Evidence map›Paper›PMID 39345207›Full record

ReviewPharmaceutical biology2024

Epigallocatechin-3-gallate at the nanoscale: a new strategy for cancer treatment.

Wenxue Sun, Yizhuang Yang, Cuiyun Wang, Mengmeng Liu, Jianhua Wang, Sen Qiao, Pei Jiang, Changgang Sun, Shulong Jiang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmaceutical biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Role of cystathionine-β-synthase and hydrogen sulfide in down syndrome.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Review
  13. Review
  14. Review
  15. Reprogramming of fatty acid metabolism in thyroid cancer: Potential targets and mechanisms.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025
    Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Wenxue SunCollege of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
Yizhuang YangDepartment of Pharmacy, Guilin Medical University, Guilin, China.
Cuiyun WangDepartment of Pharmacy, Jining NO.1 People's Hospital, Shandong First Medical University, Jining, China.
Mengmeng LiuDepartment of Pharmacy, Jining NO.1 People's Hospital, Shandong First Medical University, Jining, China.
Jianhua WangCollege of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
Sen QiaoHepatological Surgery Department, Jining NO.1 People's Hospital, Shandong First Medical University, Jining, China.
Pei JiangTranslational Pharmaceutical Laboratory, Jining NO.1 People's Hospital, Shandong First Medical University, Jining, China.
Changgang SunCollege of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
Shulong JiangClinical Medical Laboratory Center, Jining NO.1 People's Hospital, Shandong First Medical University, Jining, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextEpigallocatechin-3-gallate (EGCG), the predominant catechin in green tea, has shown the potential to combat various types of cancer cells through its ability to modulate multiple signaling pathways. However, its low bioavailability and rapid degradation hinder its clinical application.

objectiveThis review explores the potential of nanoencapsulation to enhance the stability, bioavailability, and therapeutic efficacy of EGCG in cancer treatment.

methodsWe searched the PubMed database from 2019 to the present, using 'epigallocatechin gallate', 'EGCG', and 'nanoparticles' as search terms to identify pertinent literature. This review examines recent nano-engineering technology advancements that encapsulate EGCG within various nanocarriers. The focus was on evaluating the types of nanoparticles used, their synthesis methods, and the technologies applied to optimize drug delivery, diagnostic capabilities, and therapeutic outcomes.

resultsNanoparticles improve the physicochemical stability and pharmacokinetics of EGCG, leading to enhanced therapeutic outcomes in cancer treatment. Nanoencapsulation allows for targeted drug delivery, controlled release, enhanced cellular uptake, and reduced premature degradation of EGCG. The studies highlighted include those where EGCG-loaded nanoparticles significantly inhibited tumor growth in various models, demonstrating enhanced penetration and efficacy through active targeting mechanisms.

conclusionsNanoencapsulation of EGCG represents a promising approach in oncology, offering multiple therapeutic benefits over its unencapsulated form. Although the results so far are promising, further research is necessary to fully optimize the design of these nanosystems to ensure their safety, efficacy, and clinical viability.

Indexed as

CatechinNanoparticlesNeoplasmsAnimalsBiological AvailabilityDrug CarriersDrug Delivery SystemsHumansTeaCatechinDrug Carriersepigallocatechin gallateTeacatechinsEGCGmedicinal chemistrynanomedicine

Identifiers

PMID39345207
PMCPMC11443569

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.